Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Gilead Sciences Inc (NASDAQ:GILD) recently filed its 10-Q report ... This growth is largely due to higher demand and average ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

Gilead Sciences, Inc. (NASDAQ:GILD ... third quarter pricing dynamics discussed earlier that are not expected to repeat. Turning to Slide 10, Biktarvy third quarter sales of $3.5 billion increased 13% ...

Gilead Sciences has underperformed the broader market ... citing strong Q3 performance driven by Veklury and Biktarvy. Although the stock trades at a premium to the mean price target of $87. ...

Elsewhere, Gilead Sciences remains a leader in the HIV drug market thanks to therapies like Biktarvy, the top-prescribed HIV regimen in the U.S., with a more than 49% share of the market.